Complement C3 is one of the laboratory markers clinicians follow in systemic lupus erythematosus because it sits at the center of the complement system. When lupus immune complexes activate complement, C3 may be consumed and its blood level can fall. A low or downward-trending result can therefore support evidence of active disease, including lupus nephritis—but it cannot locate inflammation or prove that a flare is occurring.
The safest interpretation combines C3 with C4, anti-double-stranded DNA antibodies, symptoms, blood counts, blood pressure, kidney function, urinalysis, and urine protein. Some patients have active lupus with normal C3, while others have chronically low C3 when their disease is quiet. Infection, liver disease, protein loss, inherited complement abnormalities, pregnancy, and complement-directed medicines can also affect the result. A personal trend is often more informative than one isolated value.
- C3 is a central complement protein used by the classical, lectin, and alternative pathways.
- Low C3 can reflect immune consumption in active lupus, but it is not specific to lupus.
- Falling C3 may raise concern for nephritis when urine protein, blood, casts, or kidney-function changes are also present.
- Normal C3 does not rule out a lupus flare or kidney inflammation.
- Treatment decisions should follow objective organ findings, not a C3 number alone.
Table of Contents
- What C3 does in the immune system
- Why lupus can lower C3
- C3 and lupus nephritis
- Reading low, normal, and high results
- How C3 fits with other lupus tests
- Special situations and confounders
- Turning a result into a care plan
What C3 does in the immune system
Complement is a coordinated group of proteins that helps remove microbes, immune complexes, and injured cells. Activation can begin through the classical pathway, the lectin pathway, or the alternative pathway. All three routes converge on C3.
When C3 is activated, it is cleaved into biologically active fragments. C3b can attach to a target and make it easier for immune cells to clear. Other fragments help amplify inflammation and support formation of the terminal membrane attack complex. This central position explains why C3 can fall in many different immune and infectious conditions, not only lupus.
A standard C3 blood test usually measures the concentration of the protein in serum or plasma by an immunochemical method. It does not directly measure how well the entire pathway functions and does not quantify every activation fragment. This differs from the CH50 test, which evaluates combined classical-pathway and terminal-pathway function.
C3 is produced mainly in the liver, with additional local production by other cells and tissues. Its circulating level reflects a balance among:
- Production.
- Activation and consumption.
- Loss from the bloodstream.
- Genetic baseline.
- Laboratory and biologic variation.
The test is usually reported in milligrams per deciliter, grams per liter, or another laboratory-specific unit. Reference intervals differ by age, analyzer, reagent, and laboratory population. A result must be compared with the range printed on that specific report.
C3 is also an acute-phase reactant. During inflammation, the liver may increase production. That can partially offset immune consumption and leave the measured concentration inside the reference range even when complement activation is occurring. This is one reason serum C3 is useful but imperfect as a disease-activity biomarker.
The complement system has a paradoxical relationship with lupus. Adequate early complement function helps clear dying cells and immune complexes, which may protect against autoimmunity. Yet once lupus immune complexes form, complement activation can contribute to tissue inflammation and lower circulating components. Inherited deficiencies of early complement proteins can therefore increase lupus susceptibility, while acquired consumption can accompany active disease.
Why lupus can lower C3
Lupus can produce autoantibodies against nuclear material. Antibodies and antigens may combine into immune complexes that activate the classical complement pathway. As the cascade proceeds, C3 is cleaved and removed from circulation faster than it is replaced. This is often called complement consumption.
A low C3 result is most meaningful when it changes with the clinical course. Some patients show a reproducible pattern:
- C3 falls as inflammatory activity rises.
- Anti-dsDNA increases or other serologic activity appears.
- Symptoms or organ findings emerge.
- C3 recovers as treatment controls inflammation.
That pattern can make C3 a useful personal biomarker. It is not universal. Lupus is biologically heterogeneous, and different organs or flare types may not consume complement to the same degree.
Low complement is part of lupus classification frameworks because it adds immunologic evidence. The 2019 EULAR/ACR criteria award points for low C3 or C4 and more points when both are low. These are classification criteria for research populations, not a diagnostic checklist for self-interpretation. A clinician may diagnose lupus without low C3, and low C3 alone cannot diagnose lupus.
Common lupus settings associated with hypocomplementemia include:
- Active lupus nephritis.
- Immune-complex vasculitis.
- Active hematologic disease.
- Some episodes of serositis or generalized systemic activity.
- Flares with rising anti-dsDNA antibodies.
The relationship is probabilistic rather than absolute. A drop can precede a flare in some people, accompany it in others, or occur without clinically important disease. Likewise, fatigue, pain, or rash can worsen while C3 stays normal.
A clinician should avoid “treating the lab” in isolation. Escalating immunosuppression solely because C3 is slightly below range can expose a patient to infection and other toxicity without clear benefit. The result should trigger a search for objective activity: inflammatory examination findings, urine abnormalities, blood-count changes, or organ-specific evidence.
C3 and lupus nephritis
Lupus nephritis occurs when immune-mediated inflammation affects the kidneys. It can be silent early, which is why routine urine and kidney monitoring matters even when a patient feels well. Low C3 is a conventional biomarker associated with renal activity, but it is neither sufficiently sensitive nor sufficiently specific to diagnose nephritis.
Concern is greater when low or falling C3 appears with one or more of the following:
- New or increasing protein in the urine.
- Blood in the urine that is not explained by menstruation, stones, infection, or another cause.
- Cellular casts or active urine sediment.
- Rising creatinine or falling estimated glomerular filtration rate.
- New hypertension.
- Swelling in the legs, face, or around the eyes.
- Rising anti-dsDNA antibodies.
- Low C4 or low total complement activity.
A urine protein-to-creatinine ratio or timed urine collection quantifies protein loss more directly than C3. Serum creatinine estimates kidney filtration but can remain normal in early nephritis, particularly in younger adults with substantial kidney reserve. Urine sediment can reveal inflammatory features that a blood complement test cannot.
When clinically significant lupus nephritis is suspected, kidney biopsy may be required. The biopsy classifies the pattern and distinguishes active inflammation from chronic scarring, which strongly influences treatment. A low C3 cannot reveal the biopsy class or determine whether lesions are reversible.
Serial C3 can contribute to monitoring after treatment begins. Recovery toward baseline may accompany improvement, but proteinuria often resolves slowly, and clinical remission does not always equal histologic remission. Conversely, persistent low C3 may reflect ongoing systemic immune activity without proving persistent inflammatory lesions in the kidney.
Research and cohort data suggest low C3 can be associated with renal relapse risk. That does not mean an individual flare can be predicted with certainty. The useful approach is to combine trends: C3, C4, anti-dsDNA, urine protein, urine sediment, creatinine, blood pressure, adherence, and symptoms.
Current lupus nephritis guidance emphasizes regular urine testing and prompt evaluation of abnormalities. Treatment may include glucocorticoids with mycophenolate, cyclophosphamide, belimumab, or a calcineurin inhibitor in selected combinations. These choices depend on biopsy class, disease severity, prior therapy, fertility considerations, infection risk, and patient preferences—not on C3 alone.
Reading low, normal, and high results
Low C3
Low C3 means the measured concentration is below the laboratory reference interval. Possible explanations include:
- Complement consumption from active lupus or another immune-complex condition.
- Severe infection, especially when complement is being broadly activated.
- Alternative-pathway dysregulation or complement-mediated kidney disease.
- Reduced liver synthesis.
- Protein loss through kidneys or the gastrointestinal tract.
- A rare inherited C3 deficiency or regulatory-protein abnormality.
- Complement-directed therapy.
- Dilutional or other physiologic effects.
The degree matters. A small decline near the lower limit is interpreted differently from a profound, persistent reduction. Repeating an unexpected result and reviewing C4, CH50, AH50, liver tests, urine protein, and clinical history can help identify the mechanism.
Normal C3
A normal result does not rule out lupus, a flare, or nephritis. C3 can stay normal because the active process does not consume enough complement, production has increased, the person’s baseline is high, or inflammation is confined in a way that is not reflected strongly in blood.
A downward change within the normal interval may still be meaningful. For example, a patient whose stable C3 is consistently near the upper part of the range may show a large decline while remaining technically “normal.” Trend interpretation should be cautious but can add context, especially in pregnancy, when complement levels normally rise.
High C3
High C3 is generally nonspecific. It can accompany acute inflammation, infection, obesity, insulin resistance, metabolic disease, or other states that increase acute-phase protein production. A high value does not mean complement is functioning better, nor does it exclude lupus.
The clinical focus in lupus is usually on low or falling complement. An isolated high C3 rarely identifies a particular diagnosis and should not be treated by itself.
Chronically low C3
Some patients have a stable low baseline unrelated to new lupus activity. Possibilities include genetic variation, chronic complement activation, liver disease, protein loss, or an inherited complement disorder. If low C3 is longstanding and does not move with symptoms, it may be a poor flare marker for that individual.
Profound C3 deficiency can increase susceptibility to serious bacterial infections. A history of recurrent invasive infection, very early-onset autoimmunity, or repeatedly extreme results may justify immunology evaluation.
How C3 fits with other lupus tests
C3 is most useful as one piece of a coordinated panel.
| Test | What it contributes | Important limitation |
|---|---|---|
| C3 | Central complement concentration; may fall with consumption | Can be normal during active disease or low for non-lupus reasons |
| C4 | Classical-pathway component often consumed in immune-complex activity | Genetic copy number can produce a persistently low baseline |
| CH50 | Functional screen of the classical and terminal pathways | Sensitive to sample handling and absent individual components |
| Anti-dsDNA | Lupus-associated autoantibody that may track renal or systemic activity in some patients | Assays differ, and levels do not track every patient |
| Urinalysis and urine protein | Direct evidence of possible kidney involvement | Abnormalities have non-lupus causes and may require confirmation |
| Creatinine and eGFR | Estimate kidney filtration | May remain normal in early nephritis |
Patterns can offer clues:
- Low C3 plus low C4: compatible with classical-pathway consumption, including active immune-complex lupus.
- Low C3 with normal C4: may suggest alternative-pathway activation, severe infection, certain complement-mediated kidney diseases, or another process; lupus remains possible.
- Normal C3 with low C4: can occur in lupus, but persistent isolated low C4 may also reflect genetic baseline or other classical-pathway activity.
- Low C3, low C4, rising anti-dsDNA, and new urine abnormalities: a concerning constellation for active lupus nephritis that requires prompt evaluation.
- Low C3 without symptoms or organ changes: may justify repeat testing and investigation, not automatic treatment escalation.
A complete lupus laboratory assessment may also include blood counts, liver tests, inflammatory markers, antiphospholipid antibodies, and disease-specific studies. The exact combination depends on the clinical question.
Special situations and confounders
Pregnancy
Complement levels normally rise during pregnancy as part of physiologic immune adaptation. In a pregnant patient with lupus, a value that stays flat or falls—even if still inside the nonpregnant reference interval—can be more concerning than the absolute number suggests. Studies have associated lower early-pregnancy C3 and C4, or failure to show the expected increase, with flare risk, particularly in patients with prior nephritis.
Pregnancy interpretation belongs with maternal-fetal medicine and rheumatology. Preeclampsia and lupus nephritis can both cause hypertension and proteinuria, and the distinction requires a broader clinical and laboratory assessment.
Infection
Infection can lower C3 through consumption, raise it through acute-phase production, or leave it unchanged. Because lupus therapies may suppress immunity, infection must be considered before increasing immunosuppression for an apparent flare. Fever, respiratory symptoms, urinary symptoms, focal pain, or unstable vital signs warrant direct evaluation.
Liver disease and protein loss
Reduced synthesis in advanced liver disease can lower C3. Significant urinary protein loss or protein-losing enteropathy can also affect complement concentrations. Albumin, liver tests, urine protein, and the overall clinical picture help distinguish these mechanisms.
Complement inhibitors
Medicines targeting C3 or related complement steps can intentionally change C3-related measurements and functional assays. The expected pattern depends on the specific drug. Results should be interpreted according to the prescribing specialist’s monitoring protocol rather than ordinary lupus rules.
Assay and specimen variation
C3 concentration tests are generally more stable than functional complement assays, but method and laboratory differences remain. Hydration, acute illness, timing, and biologic variation can create modest changes. When a result would drive a major treatment decision, confirmation and correlation are appropriate.
Turning a result into a care plan
When C3 is low or falling, a clinician first asks whether there is objective evidence of active disease. That may lead to a focused examination, blood pressure check, complete blood count, C4, anti-dsDNA, creatinine, urinalysis, urine protein quantification, and other organ-specific testing.
Seek prompt medical review for:
- New swelling, foamy urine, visible blood in urine, or reduced urine output.
- New or severe hypertension.
- Chest pain, marked shortness of breath, confusion, seizure, or focal neurologic symptoms.
- Fever or signs of serious infection while immunosuppressed.
- Rapidly worsening rash, bruising, or profound weakness.
Questions worth asking include:
- How far is my C3 from my usual baseline?
- Did C4 and anti-dsDNA change at the same time?
- Are my urine protein, sediment, creatinine, and blood pressure reassuring?
- Could infection, liver disease, protein loss, pregnancy, or medication explain the result?
- Should the test be repeated before treatment changes?
- Has C3 reliably tracked my lupus in the past?
- What specific finding would prompt kidney biopsy or treatment adjustment?
A laboratory graph can be useful. Plotting C3 beside urine protein, creatinine, C4, anti-dsDNA, symptoms, and medication changes may reveal whether C3 is a dependable individual marker.
The best use of C3 is not to predict the future from one number. It is to recognize a pattern early enough to investigate, protect organs, and adjust care based on evidence. In lupus nephritis especially, the urine and kidney assessment carry the decisive information; C3 helps complete the picture.
References
- Complement as a Biomarker for Systemic Lupus Erythematosus (2023, PubMed)
- EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update (2024, PubMed)
- KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis (2024, PubMed)
- Systemic Lupus Erythematosus: A Review (2024, PubMed)
- Predictors of Renal Flares and Long-Term Renal Outcome in Patients With Lupus Nephritis: Results From Daily Clinical Practice (2022, PubMed)
- Complement Levels During the First Trimester Predict Disease Flare in Systemic Lupus Erythematosus Pregnancy: A Network Meta-Analysis (2023, PubMed)
Disclaimer
This article is for general education and does not diagnose a lupus flare or lupus nephritis. C3 results require interpretation by a qualified clinician alongside symptoms, urine studies, kidney function, other complement tests, medications, and personal baseline. Seek urgent medical care for severe infection symptoms, breathing difficulty, neurologic changes, sharply reduced urine output, or rapidly worsening swelling.
